Lupin, Sun Pharma and 1 other recall products in US
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-07-28 09:15 GMT | Update On 2025-07-28 09:15 GMT
Advertisement
New Delhi: Leading pharmaceutical companies, Sun Pharma, Dr Reddy's Laboratories and Lupin are recalling products from the US market due to manufacturing issues and product mix-ups, according to the US Food and Drug Administration (USFDA).
Sun Pharmaceutical Industries, headquartered in Mumbai, is recalling 5,448 bottles of a generic medication in the US.
Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg)—a drug commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD). The recall was due to a "failed dissolution specification" identified by the USFDA, PTI reported.
The drug firm initiated the Class II recall in the US on June 16 this year, it added.
Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure.
Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.